Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of lifePaz Fernández‐Ortega, Antonio Llombart‐Cussac, G Nocea et al.|Supportive Care in Cancer|2012Cited by 175
Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and PatientsGabriela Jiménez-Valerio, Oriol Casanovas, Mar Martínez‐Lozano et al.|Cell Reports|2016Cited by 119
Advanced Prostate Cancer with ATM Loss: PARP and ATR InhibitorsAntje Neeb, Johann S. de Bono, Nicolás Herranz et al.|European Urology|2020Cited by 118
Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.Sumanta Kumar Pal, Laurence Albigès, Nizar M. Tannir et al.|Journal of Clinical Oncology|2024Cited by 9
Assessment of time-to-treatment-failure (TTF) as a surrogate endpoint for overall survival (OS) to immune checkpoint inhibitor (ICI) regimens in metastatic renal cell carcinoma (mRCC): Findings from an IMDC analysis.Zachary A. Yochum, Toni K. Choueiri, Renée Maria Saliby et al.|Journal of Clinical Oncology|2025Cited by 0